|
By Brian Wilson - Lead Contributor
|
|
Thursday, 22 May 2014 07:49 |
 Yesterday we discussed the sheer extent of the recent selloff in biotech, and the buying opportunities that are available once again.
|
|
Read more...
|
|
By A. Deniken
|
|
Thursday, 22 May 2014 04:18 |
 The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low priced biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments.
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Wednesday, 21 May 2014 07:47 |
|
After a well-deserved selloff in the biotech space, we are much more comfortable with the pricing of most of the NASDAQ-traded biotech stocks that we follow.
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Tuesday, 20 May 2014 07:44 |
 Last year, Aegerion was positioning itself to utterly dominate the drug market for a rare genetic disease known as Homozygous Familial Hypercholesterolemia (HoFH) with its newly approved drug Juxtapid (lomitapide).
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Sunday, 18 May 2014 23:39 |
|
Last week, the cancer immunotherapy company Northwest Biotherapeutics (NWBO) issued a press release discussing a case study from their Phase II trial for DCVax-Direct in the treatment of solid tumors.
|
|
Read more...
|
|
By David Ibrahim
|
|
Tuesday, 08 April 2014 03:41 |
 Chief Executive Officer, Geert Kersten of Phase III drug developer CEL-SCI (AMEX:CVM) made a notable insider purchase of 170,000 Series S Warrants confirmed by a Form 4 filing reported on Monday with the Securities and Exchange Commission.
|
|
Read more...
|
|
By Scott Matusow
|
|
Thursday, 06 March 2014 10:17 |
 Synthetic Biologics (SYN) expects to present top-line data from its Trimesta/Copaxone combo Phase II multi-center clinical trial involving 164 women for the treatment of relapsing-remitting multiple sclerosis (MS) in women.
|
|
Read more...
|
|
By Scott Matusow
|
|
Tuesday, 25 February 2014 08:16 |
|
Xenoport (XNPT) focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders.
|
|
Read more...
|
|
By Scott Matusow
|
|
Thursday, 20 February 2014 08:29 |
|
Similar to how a blue-chip company might have an increase in stock price before an earnings call, small-cap developmental biotechs often increase in price before important clinical data releases, Advisory Committee Meetings (ADCOM), and U.S. Food and Drug Administration (FDA) drug approvals.
|
|
Read more...
|
|
By Scott Matusow
|
|
Friday, 14 February 2014 08:48 |
|
This week we want to highlight several biotechs with catalysts coming up in the near future. These price driving catalysts may include FDA approval decisions, FDA Advisory Committee (ADCOM) recommendations, product launches, and clinical data releases.
|
|
Read more...
|
|
|
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
|
|
Page 14 of 56 |
